Inquiry Basket
Loading ......
Sindbis Virus (SINV), a member of the Alphavirus genus within the Togaviridae family, is an enveloped, single-stranded positive-sense RNA virus that is widely distributed across the globe. First isolated in 1952 from a single Culex mosquito collected in the Sindbis village of the Nile Delta in Egypt, the virus takes its name from this region. SINV is a mosquito-borne pathogen that maintains a natural transmission cycle between mosquitoes and birds, with humans serving as accidental hosts. While human infections are generally mild and self-limiting, the virus can cause significant discomfort and occasional long-term complications, making it a notable public health concern in endemic regions.
Figure 1. Structural organization and domain architecture of Sindbis virus revealed by cryo-electron microscopy. (Geng Q,et al.2025)
SINV is a spherical virus with a diameter of approximately 70 nanometers, characterized by an outer lipid envelope derived from the host cell membrane and an inner icosahedral capsid. The viral genome is a single molecule of positive-sense RNA, approximately 11.7 kilobases in length, with a 5' cap and a 3' polyadenylated tail—features that allow it to act directly as messenger RNA (mRNA) in host cells, enabling immediate translation upon entry. The genome contains two open reading frames (ORFs) that encode all viral proteins. The 5' ORF encodes four non-structural proteins (nsP1, nsP2, nsP3, and nsP4), which are essential for viral replication and transcription. These proteins are initially translated as a single polyprotein that undergoes self-cleavage to form individual functional proteins. nsP1 acts as a methyltransferase and guanylyltransferase, responsible for capping the viral RNA. nsP2 functions as a protease and helicase, facilitating polyprotein cleavage and unwinding viral RNA during replication. nsP3 plays a role in interfering with host antiviral responses, while nsP4 is the viral RNA-dependent RNA polymerase (RdRP) that drives the synthesis of new viral genomes and subgenomic RNA.
SINV has a global distribution, with a particular presence in Africa, Europe, Asia, and Oceania. It maintains a sylvatic transmission cycle between mosquitoes (the vector) and birds (the reservoir host). A variety of mosquito species can transmit SINV, including Culex, Aedes, and Anopheles, with Culex modestus recently identified as a key vector in some European regions. Birds, including crows, sparrows, pigeons, and various migratory species, serve as the primary reservoir, harboring the virus without developing clinical disease. Migratory birds play a crucial role in the global spread of SINV, carrying the virus across geographic boundaries and introducing it to new regions.
| Diagnosis, Prevention, and Control | Details |
| Diagnosis | Diagnosis of SINV infection is challenging due to the similarity of its symptoms to other mosquito-borne diseases, such as dengue fever, chikungunya fever, and Zika virus infection. Laboratory diagnosis relies on detecting viral RNA in blood samples using reverse transcription-polymerase chain reaction (RT-PCR) during the acute phase of infection, or detecting specific antibodies (IgM and IgG) using serological tests such as enzyme-linked immunosorbent assay (ELISA) during the convalescent phase. These tests help distinguish SINV from other similar viruses and confirm the diagnosis. |
| Prevention | Currently, there are no approved vaccines or specific antiviral drugs for the prevention or treatment of SINV infection. Prevention and control strategies focus on reducing mosquito populations and minimizing human exposure to mosquito bites. This includes measures such as eliminating standing water (where mosquitoes breed), using insect repellents, wearing protective clothing, and installing screens on windows and doors. Public health surveillance is also crucial, as monitoring mosquito populations and viral activity helps identify potential outbreaks and implement targeted control measures. |
| Control | For individuals infected with SINV, treatment is supportive, focusing on relieving symptoms. This includes rest, hydration, and the use of over-the-counter medications to reduce fever, pain, and inflammation. In cases of severe joint pain, anti-inflammatory drugs may be prescribed to alleviate discomfort. Most patients recover fully without the need for hospitalization, and fatalities from SINV infection are extremely rare. |
Sindbis virus infection in humans typically manifests as an acute febrile illness known as Sindbis fever. The incubation period averages approximately seven days, after which symptoms develop abruptly. The clinical triad most characteristic of SINV disease comprises arthritis/arthralgia, rash, and mild fever, often accompanied by malaise and fatigue. The arthralgia is typically symmetrical and affects multiple joints, with a predilection for the small joints of the hands and feet, as well as the wrists, elbows, ankles, and knees. Tendinitis is common, frequently involving the Achilles tendon and hand extensor tendons, adding to patient discomfort. Joint pain can be severe enough to limit mobility and daily activities. The rash typically appears around the same time as joint symptoms, though one may precede the other by a few days. It begins as macules on the torso before spreading to the arms, legs, palms, soles, and occasionally the head. These macules evolve into papules that may vesiculate, particularly on pressure points such as the palms and soles. Vesicles can become hemorrhagic in severe cases. As the eruption fades, it may leave a brownish discoloration, and rash recurrence during convalescence has been reported.
Sindbis Virus is a globally distributed mosquito-borne alphavirus that causes mild to moderate illness in humans, characterized by fever, rash, and severe joint pain. While it is not a major cause of severe disease or death, its widespread distribution and potential for long-term complications make it a significant public health concern. The virus maintains a natural transmission cycle between mosquitoes and birds, with humans serving as accidental hosts, and its spread is influenced by factors such as bird migration and climate change. Despite the lack of approved vaccines or specific treatments, supportive care and mosquito control measures are effective in managing infections and reducing transmission. As a model organism, SINV continues to contribute to our understanding of RNA virus biology and antiviral immunity, paving the way for future advancements in virology and public health.
Reference
| Target | Cat. No. | Product Name | Host | |
| SINV | DAGA-291 | SINV Envelope Antigen 2 (aa 137-493) [His] | E. coli | Inquiry |
Loading ......
